Advertisement

Retinoblastoma: Evaluation and Diagnosis

  • Brian P. MarrEmail author
  • Arun D. Singh
Chapter

Abstract

In 1809, a Scottish surgeon named James Wardrop wrote a monograph where he described a subset of fungus haematodes distinguishing them from other cases of “soft cancer,” “medullary sarcoma,” or inflammation. He was the first to recognize retinoblastoma (RB) as a discrete tumor arising primarily from the retina [1]. Virchow in 1864 used the name glioma retinae because of retinoblastoma’s similarity to intracranial glial tumors. Verhoeff, in 1922, observed the retinal origin and the presence of immature, embryonic cells that formed the tumor and coined the term retinoblastoma. In 1926, the American Ophthalmological Society accepted the term retinoblastoma and the older terms, such as glioma retinae and fungus haematodes, were abandoned [2]. In 1809, it was the astute clinical observations and descriptions of the disease that made the diagnosis of what we now know as retinoblastoma.

Keywords

Retinal Detachment Fluorescein Angiography Posterior Pole Corneal Diameter Eyelid Speculum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Kivelä T. 200 years of success initiated by James Wardrop’s 1809 monograph on retinoblastoma. Acta Ophthalmol. 2009;87:810–2.PubMedCrossRefGoogle Scholar
  2. 2.
    Dunphy EB. The story of retinoblastoma. Am J Ophthalmol. 1964;58:539–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Maki JL, Marr BP, Abramson DH. Diagnosis of retinoblastoma: how good are referring physicians? Ophthalmic Genet. 2009;30:199–205.PubMedCrossRefGoogle Scholar
  4. 4.
    Shields CL, Shields JA, Baez K, Cater JR, De Potter P. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer. 1994;73:692–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Gallie BL, Ellsworth RM, Abramson DH, Phillips RA. Retinoma: spontaneous regression of retinoblastoma or benign manifestation of the mutation? Br J Cancer. 1982;45:513–21.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Lin BA, Messieha ZS, Hoffman WE. Safety and efficacy of pediatric general anesthesia by laryngeal mask airway without intravenous access. Int J Clin Med. 2011;2:328–31.CrossRefGoogle Scholar
  7. 7.
    Sterns GK, Coleman DJ, Ellsworth RM. Characterization and evaluation of retinoblastoma by ultrasonography. Bibl Ophthalmol. 1975;83:125–9.PubMedGoogle Scholar
  8. 8.
    Abramson DH, Ellsworth RM. Ancillary tests for the diagnosis of retinoblastoma. Bull N Y Acad Med. 1980;56:221–31.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Liu CY, Jonna G, Francis JH, Marr BP, Abramson DH, Brodie SE. Non-selectivity of ERG reductions in eyes treated for retinoblastoma. Doc Ophthalmol. 2014;128:13–23.PubMedCrossRefGoogle Scholar
  10. 10.
    Francis JH, Abramson DH, Marr BP, Brodie SE. Ocular manipulation reduces both ipsilateral and contralateral electroretinograms. Doc Ophthalmol. 2013;127:113–22.PubMedCrossRefGoogle Scholar
  11. 11.
    Albert DM. Trilateral retinoblastoma: insights into histogenesis and management. Surv Ophthalmol. 1998;43:59–70.PubMedCrossRefGoogle Scholar
  12. 12.
    de Graaf P, Göricke S, Rodjan F, Galluzzi P, Maeder P, Castelijns JA, Brisse HJ, European Retinoblastoma Imaging Collaboration (ERIC). Guidelines for imaging retinoblastoma: imaging principles and MRI standardization. Pediatr Radiol. 2012;42:2–14.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Abramson DH, Frank CM, Susman M, Whalen MP, Dunkel IJ, Boyd 3rd NW. Presenting signs of retinoblastoma. J Pediatr. 1998;132(3 Pt 1):505–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Ophthalmic OncologyCole Eye Institute, Cleveland ClinicClevelandUSA

Personalised recommendations